Fundamental Analysis of PEAR THERAPEUTICS INC(NASDAQ:PEAR) stock

Fundamental Rating

PEAR gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 40 industry peers in the Health Care Technology industry. PEAR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PEAR is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year PEAR has reported negative net income.

In the past year PEAR has reported a negative cash flow from operations.

1.2 Ratios

The profitability ratios for PEAR are negative, so there is not much use analyzing them.

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

PEAR's Gross Margin of 41.75% is on the low side compared to the rest of the industry. PEAR is outperformed by 64.44% of its industry peers.

The Profit Margin and Operating Margin are not available for PEAR so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	41.75%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

PEAR does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for PEAR has been increased compared to 1 year ago.

PEAR has a worse debt/assets ratio than last year.

2.2 Solvency

Based on the Altman-Z score of -8.36, we must say that PEAR is in the distress zone and has some risk of bankruptcy.

The Altman-Z score of PEAR (-8.36) is worse than 75.56% of its industry peers.

There is no outstanding debt for PEAR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-8.36

ROIC/WACCN/A

WACC10.97%

2.3 Liquidity

PEAR has a Current Ratio of 1.48. This is a normal value and indicates that PEAR is financially healthy and should not expect problems in meeting its short term obligations.

Looking at the Current ratio, with a value of 1.48, PEAR is in line with its industry, outperforming 44.44% of the companies in the same industry.

A Quick Ratio of 1.48 indicates that PEAR should not have too much problems paying its short term obligations.

PEAR has a Quick ratio (1.48) which is in line with its industry peers.

		Industry Rank	Sector Rank
Current Ratio	1.48
Quick Ratio	1.48

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 11.78% over the past year.

PEAR shows a strong growth in Revenue. In the last year, the Revenue has grown by 201.66%.

EPS 1Y (TTM)11.78%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q67.16%

Revenue 1Y (TTM)201.66%

Revenue growth 3YN/A

Revenue growth 5YN/A

Revenue growth Q2Q-39.04%

3.2 Future

PEAR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 23.42% yearly.

PEAR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 81.05% yearly.

EPS Next Y10%

EPS Next 2Y28.84%

EPS Next 3Y16.96%

EPS Next 5Y23.42%

Revenue Next Year119.68%

Revenue Next 2Y113.93%

Revenue Next 3Y110.5%

Revenue Next 5Y81.05%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PEAR. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PEAR. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEAR's earnings are expected to grow with 16.96% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y28.84%

EPS Next 3Y16.96%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for PEAR!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

PEAR THERAPEUTICS INC

NASDAQ:PEAR (4/18/2023, 7:27:07 PM)

After market: 0.0287 0 (-1.71%)

0.0292

-0.02 (-38.91%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupHealth Care Equipment & Services

GICS IndustryHealth Care Technology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap4.17M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	N/A
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	41.75%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.13

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	1.48
Quick Ratio	1.48
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)11.78%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y10%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)201.66%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

PEAR THERAPEUTICS INC (PEAR)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens